UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 62

Sortiert nach

Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials

Antioxidants, 2020-08, Vol.9 (8), p.692

2020

Link zum Volltext

Verfügbarkeit prüfen

Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process

Scientific reports, 2020-03, Vol.10 (1), p.4790, Article 4790

2020

Link zum Volltext

Verfügbarkeit prüfen

Prenatal Administration of Oleic Acid or Linolenic Acid Reduces Neuromorphological and Cognitive Alterations in Ts65dn Down Syndrome Mice

The Journal of nutrition, 2020-06, Vol.150 (6), p.1631-1643

2020

Link zum Volltext

Verfügbarkeit prüfen

Prenatal, but not Postnatal, Curcumin Administration Rescues Neuromorphological and Cognitive Alterations in Ts65Dn Down Syndrome Mice

The Journal of nutrition, 2020-09, Vol.150 (9), p.2478-2489

2020

Link zum Volltext

Verfügbarkeit prüfen

Cellular Senescence in Neurodegenerative Diseases

Frontiers in cellular neuroscience, 2020-02, Vol.14, p.16-16

2020

Link zum Volltext

Verfügbarkeit prüfen

Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice

Brain, behavior, and immunity, 2018-10, Vol.73, p.235-251

2018

Link zum Volltext

Verfügbarkeit prüfen

Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome

Neurochemical research, 2016-11, Vol.41 (11), p.2904-2913

2016

Link zum Volltext

Verfügbarkeit prüfen

Signalling Pathways Implicated in Alzheimer′s Disease Neurodegeneration in Individuals with and without Down Syndrome

International journal of molecular sciences, 2020-09, Vol.21 (18), p.6906

2020

Link zum Volltext

Verfügbarkeit prüfen

Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome

Behavioural brain research, 2017-09, Vol.334, p.142-154

2017

Link zum Volltext

Verfügbarkeit prüfen

Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome

Journal of Alzheimer's disease, 2010-01, Vol.21 (1), p.277

2010

Link zum Volltext

Verfügbarkeit prüfen

Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities

Neural plasticity, 2012-01, Vol.2012, p.584071-26

2012

Link zum Volltext

Verfügbarkeit prüfen

Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome

PloS one, 2014-09, Vol.9 (9), p.e106572-e106572

2014

Link zum Volltext

Verfügbarkeit prüfen

Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes

Neurobiology of disease, 2017-10, Vol.106, p.76-88

2017

Link zum Volltext

Verfügbarkeit prüfen

Nuclear Reorganization in Hippocampal Granule Cell Neurons from a Mouse Model of Down Syndrome: Changes in Chromatin Configuration, Nucleoli and Cajal Bodies

International journal of molecular sciences, 2021-01, Vol.22 (3), p.1259

2021

Link zum Volltext

Verfügbarkeit prüfen

Behavioral, cognitive and biochemical responses to different environmental conditions in male Ts65Dn mice, a model of Down syndrome

Behavioural brain research, 2005-09, Vol.163 (2), p.174-185

2005

Link zum Volltext

Verfügbarkeit prüfen

Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene

Neurobiology of disease, 2018-02, Vol.110, p.206-217

2018

Link zum Volltext

Verfügbarkeit prüfen

Early postnatal oleic acid administration enhances synaptic development and cognitive abilities in the Ts65Dn mouse model of Down syndrome

Nutritional neuroscience, 2022-07, Vol.25 (7), p.1400-1412

2022

Link zum Volltext

Verfügbarkeit prüfen

Oxidative-Stress-Associated Proteostasis Disturbances and Increased DNA Damage in the Hippocampal Granule Cells of the Ts65Dn Model of Down Syndrome

Antioxidants, 2022-12, Vol.11 (12), p.2438

2022

Link zum Volltext

Verfügbarkeit prüfen

Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome

Progress in brain research, 2020, Vol.251, p.245-268

2020

Link zum Volltext

Verfügbarkeit prüfen

Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer's Disease

Frontiers in pharmacology, 2021-04, Vol.12, p.613211-613211

2021

Link zum Volltext

Verfügbarkeit prüfen

Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome

Journal of pineal research, 2013-04, Vol.54 (3), p.346-358

2013

Link zum Volltext

Verfügbarkeit prüfen

Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome

The Journal of neuroscience, 2013-02, Vol.33 (9), p.3953-3966

2013

Link zum Volltext

Verfügbarkeit prüfen

Apoptosis in Down’s syndrome: lessons from studies of human and mouse models

Apoptosis (London), 2013-02, Vol.18 (2), p.121-134

2013

Link zum Volltext

Verfügbarkeit prüfen

Melatonin Enhances the Usefulness of Ionizing Radiation: Involving the Regulation of Different Steps of the Angiogenic Process

Frontiers in physiology, 2019-07, Vol.10, p.879-879

2019

Link zum Volltext

Verfügbarkeit prüfen

Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome

Behavioural brain research, 2008-04, Vol.188 (2), p.355-367

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 62

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(60)
Mit Volltextzugriff
(55)

Publikationsform

Artikel
(61)
Tagungsberichte
(1)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(6)

Menü

Weitere Dienste

Einstellungen

Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials

Usefulness of melatonin as complementary to chemotherapeutic agents at different stages of the angiogenic process

Prenatal Administration of Oleic Acid or Linolenic Acid Reduces Neuromorphological and Cognitive Alterations in Ts65dn Down Syndrome Mice

Prenatal, but not Postnatal, Curcumin Administration Rescues Neuromorphological and Cognitive Alterations in Ts65Dn Down Syndrome Mice

Cellular Senescence in Neurodegenerative Diseases

Anti-IL17 treatment ameliorates Down syndrome phenotypes in mice

Chronic Melatonin Administration Reduced Oxidative Damage and Cellular Senescence in the Hippocampus of a Mouse Model of Down Syndrome

Signalling Pathways Implicated in Alzheimer′s Disease Neurodegeneration in Individuals with and without Down Syndrome

Pre- and post-natal melatonin administration partially regulates brain oxidative stress but does not improve cognitive or histological alterations in the Ts65Dn mouse model of Down syndrome

Memantine normalizes several phenotypic features in the Ts65Dn mouse model of Down syndrome

Mouse Models of Down Syndrome as a Tool to Unravel the Causes of Mental Disabilities

Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome

Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes

Nuclear Reorganization in Hippocampal Granule Cell Neurons from a Mouse Model of Down Syndrome: Changes in Chromatin Configuration, Nucleoli and Cajal Bodies

Behavioral, cognitive and biochemical responses to different environmental conditions in male Ts65Dn mice, a model of Down syndrome

Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene

Early postnatal oleic acid administration enhances synaptic development and cognitive abilities in the Ts65Dn mouse model of Down syndrome

Oxidative-Stress-Associated Proteostasis Disturbances and Increased DNA Damage in the Hippocampal Granule Cells of the Ts65Dn Model of Down Syndrome

Translational validity and implications of pharmacotherapies in preclinical models of Down syndrome

Bexarotene Impairs Cognition and Produces Hypothyroidism in a Mouse Model of Down Syndrome and Alzheimer's Disease

Long-term oral administration of melatonin improves spatial learning and memory and protects against cholinergic degeneration in middle-aged Ts65Dn mice, a model of Down syndrome

Reducing GABAA α5 receptor-mediated inhibition rescues functional and neuromorphological deficits in a mouse model of down syndrome

Apoptosis in Down’s syndrome: lessons from studies of human and mouse models

Melatonin Enhances the Usefulness of Ionizing Radiation: Involving the Regulation of Different Steps of the Angiogenic Process

Effects of chronic administration of SGS-111 during adulthood and during the pre- and post-natal periods on the cognitive deficits of Ts65Dn mice, a model of Down syndrome

Suchergebnisse filtern